EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma

Jonhoi Smith, Melvin Field iD, Kiminobu Sugaya iD

Genes · 2023

DOI: 10.3390/genes14061276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2023. Verfasst von Jonhoi Smith und 2 weiteren Autor:innen. Beteiligte Einrichtung: Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCF internal funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is an aggressive and incurable primary brain tumor that harbors therapy-resistant cancer stem cells (CSCs). Due to the limited effectiveness of conventional chemotherapies and radiation treatments against CSCs, there is a critical need for the development of innovative therapeutic approaches. Our previous research revealed the significant expression of embryonic stemness genes, NANOG and OCT4, in CSCs, suggesting their role in enhancing cancer-specific stemness and drug resistance. In our current study, we employed RNA interference (RNAi) to suppress the expression of these genes and observed an increased susceptibility of CSCs to the anticancer drug, temozolomide (TMZ). Suppression of NANOG expression induced cell cycle arrest in CSCs, specifically in the G0 phase, and it concomitantly decreased the expression of PDK1. Since PDK1 activates the PI3K/AKT pathway to promote cell proliferation and survival, our findings suggest that NANOG contributes to chemotherapy resistance in CSCs through PI3K/AKT pathway activation. Therefore, the combination of TMZ treatment with RNAi targeting NANOG holds promise as a therapeutic strategy for GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell Line, TumorTemozolomideDrug ResistanceNeoplastic Stem CellsNanog Homeobox Protein

Stichwörter der Autor:innen

NANOGOCT4PI3K/AKTRNAiTMZcancer stem cellsglioblastomastemness genes

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTemozolomideNANOG protein, humanNanog Homeobox Protein

Autor:innen und Institutionen

  • Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
  • Orlando Neurosurgery, AdventHealth Neuroscience Institute, Orlando, FL 32803, USA.

ORCID-Profile: Melvin Field, Kiminobu Sugaya

Förderung

  • UCF internal funding

Zitieren

APA

Smith, J., Field, M., & Sugaya, K. (2023). Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma. Genes. https://doi.org/10.3390/genes14061276

Vancouver

Smith J, Field M, Sugaya K. Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma. Genes. 2023. doi:10.3390/genes14061276

BibTeX
@article{Smith2023,
  author = {Smith, Jonhoi and Field, Melvin and Sugaya, Kiminobu},
  title = {Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma},
  journal = {Genes},
  year = {2023},
  doi = {10.3390/genes14061276}
}
Kostenlos starten →